难治性甲状腺癌的的靶向治疗-华中科技大学协和医院.pptVIP

47%的病人需要减少剂量 不良事件：手足红斑、疹，骨肌疼痛，瘙痒症，高血压，腹泻，疲劳，体重减轻，口腔炎，秃发，腹胀，情绪改变等 2008年NCCN同意sorafenib临床进展或有症状的碘抵抗的乳头状癌的治疗 阿西替尼Axitinib（AG-013736) 口服多靶点酪氨酸激酶抑制剂 同时具有选择性抑制VEGFRs Axitinib Rixe et al 2007 renal cell carcinoma Cohen et al 2008 advanced thyroid cancer multicenter phase 2 study 60 case 30%PR 38% SD 4 months median PFS 18 months PTC 27% PR 40%SD Motesanib(AMG 706) Motesanib is a multi-targeted tyrosine kinase inhibitor that targets the VEGFRs, PDGFR, and c-kit multicenter international phase II trial of motesanib 93 patients with radioiodine-resistant, progressive DTC